Patents by Inventor Malik Bisserier

Malik Bisserier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EPAC1 INHIBITORS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20230030517
    Abstract: The present invention relates to the treatment of idiopathic pulmonary fibrosis. Today, there is no cure for IFF. The inventors showed that EPAC1 inhibitors, in particular CE3F4 and AM-001, represent a promising therapeutic strategy for treating patients with pulmonary fibrosis. The present invention thus relates to an EPAC1 inhibitor for use in the treatment and/or prevention of idiopathic pulmonary fibrosis.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 2, 2023
    Inventors: Malik BISSERIER, Frank LEZOUALC'H, Lahouaria HADRI
  • Tetrahydroquinoline derivatives and their use as Epac inhibitors
    Patent number: 10093627
    Abstract: The invention relates to tetrahydroquinoline derivatives and their use in the treatment and/or the prevention of a disease wherein the Epac protein is involved, such as inflammation, cancer, vascular diseases, kidney diseases, cognitive disorders and cardiac diseases.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: October 9, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PAUL SABATIER TOULOUSE III, UNIVERSITE PARIS-SUD, UNIVERSITE D'ORLEANS
    Inventors: Frank Lezoualc'h, Rodolphe Fischmeister, Malik Bisserier, Pascal Bouyssou, Jean-Paul Blondeau, Delphine Courilleau
  • Tetrahydroquinoline Derivatives and Their Use as Epac Inhibitors
    Publication number: 20180009757
    Abstract: The invention relates to tetrahydroquinoline derivatives and their use in the treatment and/or the prevention of a disease wherein the Epac protein is involved, such as inflammation, cancer, vascular diseases, kidney diseases, cognitive disorders and cardiac diseases.
    Type: Application
    Filed: July 27, 2017
    Publication date: January 11, 2018
    Inventors: Frank Lezoualc'h, Rodolphe Fischmeister, Malik Bisserier, Pascal Bouyssou, Jean-Paul Blondeau, Delphine Courilleau
  • Tetrahydroquinoline derivatives and their use as Epac inhibitors
    Patent number: 9751838
    Abstract: The invention relates to tetrahydroquinoline derivatives and their use in the treatment and/or the prevention of a disease wherein the Epac protein is involved, such as inflammation, cancer, vascular diseases, kidney diseases, cognitive disorders and cardiac diseases.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: September 5, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paul Sabatier Toulouse III, Universite Paris-Sud, Universite d'Orleans
    Inventors: Frank Lezoualc'h, Rodolphe Fischmeister, Malik Bisserier, Pascal Bouyssou, Jean-Paul Blondeau, Delphine Courilleau
  • TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS EPAC1 INHIBITORS FOR THE TREATMENT OF MYOCARDIAL INFARCTION INJURY
    Publication number: 20170079970
    Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a method for providing cardioprotection in a subject who experienced a myocardial infarction comprising administering the subject with a therapeutically effective amount of at least one EPAC1 inhibitor.
    Type: Application
    Filed: March 20, 2015
    Publication date: March 23, 2017
    Inventors: Frank LEZOUALC'H, Pierre SICARD, Malik BISSERIER
  • TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS EPAC INHIBITORS
    Publication number: 20150252002
    Abstract: The invention relates to tetrahydroquinoline derivatives and their use in the treatment and/or the prevention of a disease wherein the Epac protein is involved, such as inflammation, cancer, vascular diseases, kidney diseases, cognitive disorders and cardiac diseases.
    Type: Application
    Filed: September 17, 2013
    Publication date: September 10, 2015
    Inventors: Frank Lezoualc'h, Rodolphe Fischmeister, Malik Bisserier, Pascal Bouyssou, Jean-Paul Blondeau, Delphine Courilleau